Optimizing Therapies for Severe Ulcerative Colitis

Ellen Scherl, MD
Weill Cornell Medical College
New York, NY

Didactic Lecture

Viewing Options


Topic Information

Target Audience

This enduring activity has been designed to meet the educational needs of gastroenterologists, physician assistants, and nurse practitioners involved in the management of inflammatory bowel disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Discuss the natural history of patients with severe UC who present with an initial severe attack

Understand the rationale for early aggressive treatment in patients with severe UC

Discuss emerging evidence exploring optimal treatment approaches for patients with severe UC

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University School of Pharmacy and the Gi Health Foundation (GiHF). Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

To Participate and Claim Credit

To Participate and Claim Credit View the internet based webcast via up to date browser. Achieve a 70% passing grade on post-test. Complete and return Evaluation/Request for Credit Form. Certificate of Credit or Participation will be sent via email within 4-6 weeks.

Credit Designation

Purdue University College of Pharmacy designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s) . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: February 16, 2015Expiration Date: February 16, 2016   
*This program has expired. CME credit is no longer available.

Faculty, Staff and Reviewer Disclosure Statement

All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Faculty Disclosure

Dr. Ellen J. Scherl AGAF, FACG, FACP, FASGE Director, Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts Professor of Inflammatory Bowel Disease Professor of Clinical Medicine Weill Cornell Medical College of ComeII University/ New York Presbyterian Hospital Adjunct Professor of Medicine at Columbia University College of Physicians and Surgeons.

Grant/Research Support:
Abbott (AbbVie), AstraZeneca, CCFA, Elan, Janssen Research & Development, Millennium Pharmaceuticals, National Institute of Health (NIH), New York Crohn's Foundation, Mesoblast (formerly Osiris Therapeutics), Pfizer, Prometheus Laboratories, UCB, UCSF-CCF A Clinical Research Alliance.

Consultant/Advisory Board:
AbbVie, Crohn's and Colitis Foundation of America (CCF A), GIHealth Foundation, Janssen, Prometheus, Protagonist Therapeutics, Sal ix, Takeda Pharmaceuticals, UCB.

GIHealth Foundation for non-branded speaker's bureau, Janssen for non-branded speaker's bureau.

This program is supported by Educational grants from AbbVie, Janssen Biotech, Inc., Prometheus Laboratories and Takeda Pharmaceuticals.

© Copyright 2013-2020 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.